Table 3. SIRs of specific cancer types among patients with iron deficiency anemia (IDA) after excluding the first year of observation post IDA.
| Site of cancers | Total | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) | |
| All cancers | 1,135 | 795.98 | 1.43 (1.34–1.51) | 436 | 280.90 | 1.55 (1.41–1.70) | 699 | 515.08 | 1.36 (1.26–1.46) |
| Head and neck | 58 | 43.71 | 1.33 (1.01–1.72) | 38 | 28.17 | 1.35 (0.95–1.85) | 20 | 15.54 | 1.29 (0.79–1.99) |
| Digestive system | 467 | 268.03 | 1.74 (1.59–1.91) | 232 | 121.06 | 1.92 (1.68–2.18) | 235 | 146.97 | 1.60 (1.40–1.82) |
| Esophagus | 18 | 10.00 | 1.80 (1.07–2.85) | 16 | 8.06 | 1.99 (1.14–3.22) | 2 | 1.94 | 1.03 (0.12–3.73) |
| Stomach | 54 | 37.74 | 1.43 (1.07–1.87) | 26 | 17.86 | 1.46 (0.95–2.13) | 28 | 19.88 | 1.41 (0.94–2.04) |
| Colon and rectum | 171 | 115.32 | 1.48 (1.27–1.72) | 75 | 44.70 | 1.68 (1.32–2.10) | 96 | 70.62 | 1.36 (1.10–1.66) |
| Liver | 185 | 81.50 | 2.27 (1.95–2.62) | 100 | 41.64 | 2.40 (1.95–2.92) | 85 | 39.86 | 2.13 (1.70–2.64) |
| Extrahepatic biliary tract | 15 | 9.79 | 1.53 (0.86–2.53) | 6 | 3.40 | 1.77 (0.65–3.84) | 9 | 6.39 | 1.41 (0.64–2.67) |
| Pancreas | 24 | 13.68 | 1.75 (1.12–2.61) | 9 | 5.40 | 1.67 (0.76–3.16) | 15 | 8.27 | 1.81 (1.01–2.99) |
| Lung and mediastinum | 100 | 93.57 | 1.07 (0.87–1.30) | 55 | 45.69 | 1.20 (0.91–1.57) | 45 | 47.89 | 0.94 (0.69–1.26) |
| Bone and soft tissue | 5 | 6.16 | 0.81 (0.26–1.90) | 3 | 2.17 | 1.38 (0.29–4.04) | 2 | 3.99 | 0.50 (0.06–1.81) |
| Skin | 24 | 16.69 | 1.44 (0.92–2.14) | 8 | 5.97 | 1.34 (0.58–2.64) | 16 | 10.72 | 1.49 (0.85–2.42) |
| Breast | 154 | 137.09 | 1.12 (0.95–1.32) | 0 | 0.31 | 0.00 (0.00–11.73) | 154 | 136.77 | 1.13 (0.96–1.32) |
| Genitourinary system | 192 | 144.85 | 1.33 (1.14–1.53) | 56 | 53.91 | 1.04 (0.78–1.35) | 136 | 90.94 | 1.50 (1.25–1.77) |
| Cervix | 33 | 30.99 | 1.06 (0.73–1.50) | – | – | – | 33 | 30.99 | 1.06 (0.73–1.50) |
| Uterus | 35 | 20.43 | 1.71 (1.19–2.38) | – | – | – | 35 | 20.43 | 1.71 (1.19–2.38) |
| Ovaries | 18 | 16.74 | 1.08 (0.64–1.70) | – | – | – | 18 | 16.74 | 1.08 (0.64–1.70) |
| Prostate | 30 | 33.72 | 0.89 (0.60–1.27) | 30 | 33.72 | 0.89 (0.60–1.27) | – | – | – |
| Bladder | 39 | 23.44 | 1.66 (1.18–2.27) | 14 | 13.38 | 1.05 (0.57–1.76) | 25 | 10.06 | 2.48 (1.61–3.67) |
| Kidney | 37 | 19.54 | 1.89 (1.33–2.61) | 12 | 6.82 | 1.76 (0.91–3.07) | 25 | 12.72 | 1.97 (1.27–2.90) |
| Thyroid | 37 | 24.87 | 1.49 (1.05–2.05) | 4 | 1.58 | 2.53 (0.69–6.49) | 33 | 23.29 | 1.42 (0.98–1.99) |
| Hematologic malignancies | 63 | 33.36 | 1.89 (1.45–2.42) | 32 | 12.57 | 2.55 (1.74–3.59) | 31 | 20.79 | 1.49 (1.01–2.12) |
| Non-Hodgkin's lymphoma | 26 | 17.09 | 1.52 (0.99–2.23) | 9 | 6.20 | 1.45 (0.66–2.75) | 17 | 10.88 | 1.56 (0.91–2.50) |
| Hodgkin's disease | 1 | 0.75 | 1.33 (0.03–7.41) | 1 | 0.24 | 4.23 (0.11–23.57) | 0 | 0.52 | 0.00 (0.00–7.16) |
| Multiple myeloma | 8 | 4.37 | 1.83 (0.79–3.61) | 8 | 1.83 | 4.36 (1.88–8.59) | 0 | 2.54 | 0.00 (0.00–1.45) |
| Leukemia | 28 | 11.15 | 2.51 (1.67–3.63) | 14 | 4.29 | 3.26 (1.78–5.47) | 14 | 6.85 | 2.04 (1.12–3.43) |
| All others | 35 | 27.65 | 1.27 (0.88–1.76) | 8 | 9.46 | 0.85 (0.37–1.67) | 27 | 18.19 | 1.48 (0.98–2.16) |
SIR, standardized incidence ratio; CI, confidence interval